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ABSTRACT  
Objectives: To investigate effect of different proportions of Terminalia bellerica Roxb (TB):Terminalia chebula Retz (TC):Phyllanthus emblica L. (PE) 
in triphala extract on immunological activity and to determine the possibility of applying the appropriate extract for health and immune disorders. 
Methods: The extracts with different proportions of TB: TC: PE (w/w/w), i.e.12:8:4 (F1), 4:12:8 (F2), 8:4:12 (F3) and 8:8:8 (F4), were prepared by 
decoction in water and dried under vacuum. Gallic acid, a major compound in triphala, was detected by high performance liquid chromatography 
(HPLC). The effect of the extracts on IFN-γ and IL-10 cytokine production produced by MOLT-4 cells was determined by ELISA. 
Results: The results show that F1, F4 and TB extracts significantly stimulated IFN-γ production but no alteration in IL-10 expression was observed. 
With LPS induction, F1, F2, F3 and PE extracts significantly inhibited IFN-γ production, while F2, F3, TB and TC extracts inhibited IL-10 production. 
By determining the IFN-γ/IL-10 cytokine ratio, we found that the Th1/Th2 balance after treatment with triphala extract was mainly skewed toward 
a Th1-like response. With LPS induction, only the F1 extract could restore the balance of immunity by shifting the Th2 response to a normal level. 
Conclusion: Our investigation indicates that different proportions of triphala extracts and induction conditions affect cytokine production, with a 
predominant Th1 response. F4, the equal proportion triphala extract, could be applied as a healthy herbal drink. F1, containing a high proportion of 
T. bellerica, was a promising extract as an effective therapeutic intervention against Th2 imbalance diseases such as allergy and autoimmune disease 
or for use with cancer vaccines. 
Keywords: Triphala, Immunomodulatory activity, MOLT-4 cells, Interferon-γ, Interleukin-10, Th1/Th2 balance. 
 
INTRODUCTION 
Herbs have been used for food and medicinal purposes for centuries. 
Traditional, complementary, alternative or non-conventional 
medicines are used by 70–95% of the global population, particularly 
in developing countries [1]. Nowadays, alternative medicine for the 
treatment of various diseases, including immunological disorders, is 
becoming more popular. Research interest has been focused on 
various herbs that possess immunomodulatory properties that may 
be useful in reducing the risk of various diseases and cancers [2]. 
Immune activation is an effective as well as a protective approach 
against emerging infectious diseases [3]. There have been many 
reports on the effects of herbal medicines as immunomodulators 
which alter immune function. Some effective plants have been 
developed into clinical therapeutics. Many of these traditional herbs 
are prepared as combined formulas, which may influence various 
molecular pathways. Therefore, the pharmacological activity may be 
different from combinations of individual herbs. Therapeutic success 
using these formulas may be partially due to their effects on 
cytokines. Although some mechanisms of action of herbs are unclear 
and remain to be elucidated, they are worth further study as 
potential therapeutic agents for immunological applications [2]. 
Triphala is an herbal formulation consisting of the dried and 
powdered fruits of three plants, Terminalia bellerica (family 
Combretaceae), Terminalia chebula (family Combretaceae) and 
Emblica officinalis (family Phyllanthaceae). Chemically, the fruit of T. 
bellerica had been found to contain gallic acid as an active component, 
as well as other phytochemical compounds such as ellagic acid, ethyl 
gallate, chebulagic acid and β-sitosterol [4, 5]. T. bellerica has been 
scientifically shown to possess antibacterial [6], antifungal [7], 
antioxidant [8] and hypotensive [9] effects. Moreover, our previous 
study showed that the methanolic extract of T. bellerica affected the 
mouse immune system, both in terms of the cellular and humoral 
immune responses in vitro, corresponding to its folklore applications 
[10]. T. chebula fruit is reported to possess the phytocompounds 
responsible for various activities such as antimicrobial, antioxidant, 
antiviral, anticarcinogenic, hypocholesterolemic and antispasmodic 
[11]. The fruit extract of P. emblica contains phenolic compounds such 
as anthocyanins, flavonols, ellagic acid and its derivatives [12] and is 
also a rich source of ascorbic acid [13]. It exhibits various biological 
activities, including antioxidant, anti-tumour, anti-inflammatory, anti-
bacterial and hepatoprotective activity [14, 15].  
Triphala is an Ayurvedic formulation rich in antioxidants which is 
believed to promote health, immunity and longevity [16, 17]. It is 
used to treat many diseases such as inflammation, infection, obesity, 
anaemia, fatigue, tuberculosis, AIDS [18], jaundice, constipation, 
asthma, fever and chronic ulcers [19]. Gallic acid has been identified 
as a major ingredient of triphala [20]. Typically, triphala is an herbal 
formulation containing the fruits of T. bellerica, T. chebula and P. 
emblica in equal proportions [21]. In Thailand, several proportions 
of the three fruits in triphala are used, such as 1:1:1, 12:8:4, 4:12:8 
and 8:4:12, recommended for various disorders. Triphala juice sold 
in Thailand and abroad, in particularly in India, is usually an equal 
proportion of T. bellerica, T. chebula and P. emblica in the 
formulation. The Department of Thai Traditional and 
Complementary Medicines in Thailand introduced triphala at equal 
proportion for a healthy balance and at ratio of 100:200:400 g 
(1:2:4) for immunity improvement. In Thai traditional medicine, 
different proportions of the three components in triphala are 
defined according to aetiology and season. In this study, we 
investigated the immunomodulatory activity of triphala extracts 
prepared in different proportions of T. bellerica, T. chebula and P. 
emblica. The possibility of developing an effective triphala extract or 
juice for health promotion or immune disorder was assessed. 
MATERIALS AND METHODS 
Chemicals 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), lipopolysaccharide (LPS), dimethyl sulfoxide (DMSO), 
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antibiotic-antimycotic solution (100 U penicillin, 100 µg 
streptomycin and 0.25 µg/ml amphotericin B), phosphate buffered 
saline (PBS) and gallic acid were purchased from Sigma-Aldrich 
(Germany). RPMI-1640 medium, L-glutamine and foetal bovine 
serum (FBS), were purchased from GIBCO (UK). Human IFN- and 
IL-10 ELISA kits were purchased from eBioscience Inc. (USA). 2-
propanol, acetic acid, acetonitrile and methanol (HPLC grade) were 
purchased from Merck (Germany).  
MOLT-4 cell culture 
The human leukemic T cell line (MOLT-4) was used in this study. 
The cells were maintained in RPMI-1640 medium supplemented 
with 2 mM L-glutamine and 10% FBS at 37 °C in a 5% CO2 
atmosphere. 
Plant material 
Dried fruits of Terminalia bellerica Roxb (TB), Terminalia chebula 
Retz (TC) and Phyllanthus emblica L. (PE) were purchased from an 
herbal medicine store in Phitsanulok, Thailand, and identified by a 
botanist at the Faculty of Pharmaceutical Sciences, Naresuan 
University, Phitsanulok, Thailand. A specimen was prepared and 
deposited at the Faculty of Pharmaceutical Sciences, Naresuan 
University, Phitsanulok, Thailand. 
Preparation of extracts 
The dried powder (500 g) of TB, TC and PE or triphala extract (TB: 
TC: PE of 12:8:4 (F1), 4:12:8 (F2), 8:4:12 (F3) and 8:8:8 (F4) 
(w/w/w)) were extracted by decoction in 3 l of distilled water and 
concentrated to 1 l, then filtered. The filtrate was evaporated under 
reduced pressure until dryness and the percentage yield was 
calculated. The extract was dissolved in 0.1% DMSO in PBS solution. 
Insoluble material was centrifuged and the extract was sterilised 
using a 0.2 µm filter. 0.1% DMSO in PBS solution was used as the 
control in all experiments. 
Determination of the gallic acid content by HPLC analysis 
Gallic acid in the extract was analysed by HPLC according to 
previous study [22] with appropriate modifications. The retention 
time of authentic gallic acid (30 µg/ml) was 4.8 min. The HPLC 
system consisted of a LC-20AT pump (Shimadzu, Kyoto, Japan), a 
SPD-20A UV detector (Shimadzu, Kyoto, Japan), equipped with a 
SPD-20 A system controller (Shimadzu, Kyoto, Japan) and a SIL-
10ADVP sample injector (Shimadzu, Kyoto, Japan) fitted with a 20 µl 
sample loop. The chromatographic separations were carried out on a 
Luna C18 column (250 mm×4.6 mm i.d., 5m, 250 °A from 
Phenomenex, USA). The mobile phase was acetonitrile-water-acetic 
acid (10:88:2, v/v/v). All separations were performed isocratically 
at a flow rate of 1 ml/min. Column temperature was maintained at 
room temperature (27±2 °C). The peaks were determined using a 
UV detector set at a wavelength of 270 nm. Identification was based 
on comparing retention times and UV–Vis spectral data of the peaks 
detected with the gallic acid peaks. Quantification was accomplished 
using external calibration with pure standards. The calibration 
curves were linear with r2 = 0.999. The amount of gallic acid in the 
extracts was calculated using the area under the curve in the 
chromatograms. Standard aqueous solutions of gallic acid were 
prepared, at concentrations of 0.05−0.5 µg/ml. The dried extract 
was dissolved in the mobile phase. After filtering through filter 
paper and a 0.45 µm membrane filter, the extract was injected 
directly.  
Cytokine production assay 
The production of IFN-γ and IL-10 by a human leukemic T cell line 
(MOLT-4) was measured by ELISA according to the instructions of 
the manufacturer (eBioscience, Inc. San Diego, USA). T cells (3×105 
cell) induced with 5 µg/ml LPS were treated with TB, TC and PE or 
triphala extracts (0.01, 0.1, 1 mg/ml) for 24 h at 37 °C in a 
humidified 5% CO2 incubator. Cytokine secretion into the culture 
supernatant was analysed. Briefly, a 96-well microtiter plate was 
pre-coated overnight with the capture antibody. This was followed 
by blocking and several washings, then the working standards and 
samples were added and incubated for 2 h. After further washing, 
the working detector solution containing biotinylated anti-cytokine 
monoclonal antibody and avidin-horseradish peroxidase conjugate 
was added to each well and incubated for 30 min. The substrate 
solution was then added, followed by the addition of the stop 
solution, and the absorbance was read using a microtiter plate 
reader at 450 nm. To determine Th1/Th2 balance, the IFN-γ/IL-10 
ratio was calculated.  
Cell viability assay 
Cell viability assays were assessed using a modified MTT assay [23]. 
Briefly, cell suspensions (3×105 cell) were treated with TB, TC and 
PE or triphala extracts (0.01, 0.1, 1 mg/ml) for 24 h at 37 °C in a 
humidified 5% CO2 incubator. Subsequently, 5 mg/ml MTT was 
added and incubation was continued for a further 4 h. The culture 
medium was removed by aspiration; DMSO was then added to 
dissolve the formazan crystals. The absorbance was measured at 
595 nm using a microplate reader (Bio-Tek Instrument Inc., USA). 
Viability was measured as the percentage of viable treated cells 
relative to untreated cells. 
Statistical analysis 
All experiments were performed in triplicate and the results are 
expressed as mean±SE Statistical differences (significance level of 
P<0.05) between groups were assessed using one-way analysis of 
variance, followed by multiple comparisons using Tukey’s method. 
RESULTS 
Plant extraction 
T. bellerica (TB), T. chebula (TC), P. emblica (PE) extracts and their 
mixtures in different proportions as triphala extract (F1-F4) were 
obtained. The physical appearance of the seven extracts was similar, 
i.e. a dark brown viscous gum. The percentage yield of each extract is 
shown in table 1. 
Determination of the gallic acid content by HPLC analysis 
The gallic content in T. bellerica, T. chebula, P. emblica and triphala 
extracts was analysed using HPLC. The acetonitrile-water-acetic acid 
(10:88:2, v/v/v) system as the mobile phase demonstrated good 
separation of gallic acid from the extracts. Comparison of the 
retention times of the peaks detected on the HPLC chromatograms 
of the extracts with the reference standard gallic acid revealed that 
gallic acid was the major compound in all extracts. The maximum 
amount of gallic acid was detected in P. emblica extract. For triphala 
extracts, the gallic acid level in F4 was higher than in F3, F1 and F2, 
respectively. The percentage yield of gallic acid content of each 
extracts is shown in table 1. The HPLC chromatograms of the T. 
bellerica, T. chebula, P. emblica extracts are shown in fig. 1, and those 
of the triphala extracts are shown in fig. 2.  
 
Table 1: Percentage yield of extracts and their containing gallic acid content analysed by HPLC technique 
Extract  Plant/ingredient of formulation  
(ratio by weight) 
%yield of extract 
(by weight of dried plant) 
%yield of gallic content 
(by weight of dried material) (n = 4) 
F1  TB: TC: PE (12:8:4) 30.26 0.64±0.003 
F2  TB: TC: PE (4:12:8) 21.25 0.57±0.005 
F3  TB: TC: PE (8:4:12)  21.10 0.71±0.006 
F4  TB: TC: PE (8:8:8) 26.42 0.87±0.014 
TB T. bellerica 33.00 0.41±0.003 
TC T. chebula 36.03 0.31±0.003 
PE P. emblica 33.34 2.20±0.015 
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Cytokine production assay 
MOLT-4 cells without or with LPS induction were treated with four 
triphala extracts, as well as T. bellerica, T. chebula and P. emblica 
extracts. The production of IFN-γ and IL-10 was measured by ELISA. 
The results show that F1 (0.01 and 0.1 mg/ml), F4 (1 mg/ml) and T. 
bellerica extract (0.01 mg/ml) significantly enhanced IFN-γ 
production. The maximal IFN-γ production of approximately 
166.58±36.95 pg/ml was observed with cells treated with F1 at 0.01 
mg/ml. However, none of the extracts affected IL-10 production 
compared with basal secretion.  
LPS alone markedly increased IFN-γ and mildly increased IL-10 
production, significantly. With LPS induction, F1, F2 and F3 extracts 
suppressed IFN-γ production, of which the F1 extract (0.01 mg/ml) 
provided the maximum suppression to 20.00±4.85 pg/ml. Of the 
pure extracts, the P. emblica extract (1 mg/ml) showed the 
maximum inhibition of IFN- production following LPS treatment, to 
56.00±5.40 pg/ml. Mild suppression of IL-10 was observed when 
cells were treated with F2, F3, T. bellerica and T. chebula extracts. 
The results are shown in fig. 3. 
The Th1/Th2 balance was determined by the IFN-γ/IL-10 ratio. It 
was found that all extracts mainly affected the Th1 response. 
Compared to normal secretion, the IFN-γ/IL-10 ratio in cells treated 
with the triphala extracts F1, F3 and F2, F4 was increased by 
approximately 14-fold and 10-fold, respectively, which was higher 
than that of the three single extracts. With LPS induction, only the F1 
extract decreased the IFN-γ/IL-10 ratio to close to the normal level. 
The results are shown in fig. 4. 
Cell viability assay  
The effect of T. bellerica, T. chebula, P. emblica and triphala extracts 
on MOLT-4 cell viability was assessed. All extracts allowed cell 
viability greater than 90%, i.e. the extracts were not toxic to the cells 
(data not shown). Interestingly, P. emblica, T. bellerica and F1 
extracts at high concentrations tended to slightly increase cell 
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Fig. 2: HPLC chromatogram of triphala extracts with different ratios (w/w/w) of 10 mg/ml T. bellerica, T. chebula, P. emblica extracts; (a) 
F1 (12:8:4), (b) F2 (4:12:8), (c) F3 (8:4:12) and (d) F4 (8:8:8) 
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Fig. 3: Effects of triphala extracts (F1, F2, F3 and F4), T. bellerica 
(TB), T. chebula (TC) and P. emblica (PE) on the production of 
(a) IFN-γ and (b) IL-10 by MOLT-4 cells compared with (c) IFN-
γ and (d) IL-10 following induction with 5 µg/ml LPS. Each value 
represents the mean±SE of triplicates compared to LPS; *P<0.05 
 
DISCUSSION 
To demonstrate the pharmacological activity of triphala in 
correlation with folklore remedies, four triphala extracts containing 
T. bellerica (TB), T. chebula (TC) and P. emblica (PE) in different 
proportions were mixed and extracted by decoction in boiling water, 
as in the folklore preparation. Gallic acid, a major compound in 
triphala, has been reported to possess various biological activities 
and was used as a marker for analysis. Gallic acid was detected at 
higher levels in P. emblica than that in the T. bellerica and T. chebula 
extracts. Certainly, the F3 and F4 extract composed of a high 
proportion of P. emblica contained a high amount of gallic acid. 
Cytokines are peptides and pleiotropic glycoproteins which are 
produced from various sources and have effects on various targets. 
Cytokines are significant mediators in innate and adaptive immunity 
and have effects on cell growth, cell differentiation, cell death, and 
angiogenesis and repair processed [24]. The cytokine IFN-γ is an 
important driver in resisting viral and bacterial infections and also 
induces various immune responses. IL-10 is an inflammatory 
cytokine with effects on immunoregulation; it also downregulates 
the expression of Th1 cytokines, MHC class II antigens and co-
stimulatory molecules on macrophages. Our study shows that the 
triphala F1 and F4 extracts, containing high proportions of T. 
bellerica, maximally increased IFN-γ production of about 9 to 11-
fold. At high concentrations, F1 and the T. bellerica extract tended to 
decrease IFN-γ expression.  
 
 
Fig. 4: Effects of triphala extracts (F1, F2, F3 and F4), T. bellerica 
(TB), T. chebula (TC) and P. emblica (PE) (a) without LPS and (b) 
with 5 µg/ml LPS on the IFN-γ/IL-10 ratio in MOLT-4 cells. Each 
value represents the mean±SE of triplicates 
 
This variation in the cytokine production pattern was similar to a 
previous report [25]. However, the extracts did not clearly alter IL-
10 levels, since its basal secretion is normally low. The effects of 
triphala extracts on LPS-induced cytokine production were also 
investigated. F1, F2, F3 and P. emblica extracts following LPS 
treatment significantly decreased IFN-γ production, compared to 
levels with LPS alone. The F1 extract provided the maximum 
inhibition of IFN-γ production (7.5-fold) while the F2, F3, T. bellerica 
and T. chebula extracts significantly decreased IL-10 production 
(3.5-fold). Our investigations indicate that different proportions in 
the triphala extract and the experimental conditions affect the 
cytokine production pattern. The Th1/Th2 cytokine balance is one of 
the most important regulatory mechanisms of the immune system 
and can be evaluated by measuring certain cytokine patterns, i.e. 
Th1 and Th2 profiles [26]. The Th1/Th2 ratio is a significant value 
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function. Cytokines affect both cell-mediated immunity (CMI) and 
humoral-mediated immunity (HMI). Naïve T cells are activated to 
the Th0 cell state, which expresses both Th1 and Th2 cell 
characteristics by expressing various cytokines such as IL-2, IL-4, IL-
5, IL-6, IL-10, IL-13 and IFN−γ. After activation, cytokines which 
induce an immune response through CMI such as IL-2, IL-3 IL-12, 
IFN-γ and TNF-α (Th1 cytokines) lead to a shift from HMI to CMI. In 
contrast, cytokines such as IL-4, IL-5, IL-6, IL-10 and IL-13 (Th2 
cytokines) induce to a shift from CMI to HMI [27]. Moreover, IFN-γ 
produced from Th1 cells can suppress Th2 cell progression and the 
HMI response, while Th2 cells suppress the progression and 
stimulation of Th1 cells [28,29]. Thus, pharmacologically active 
substances that can affect the Th1 or Th2 balance may be beneficial. 
However, this may depend on the cell environment or the nature of 
the pathogen (for example, the Th1 response for intracellular 
parasites and viruses and the Th2 response for extracellular 
bacteria). Moreover, Th2 cytokines are important in the immune 
response to cancer, but also lead to immune pathology such as 
allergy and autoimmune diseases [27].  
The Th1/Th2 balance, determined by the IFN-γ/IL-10 ratio in this 
study, presented the maximum ratio for the F1 and F3 extracts (14-
fold), which was greater than that with the F2 and F4 extracts (10-
fold). These results indicate that triphala extracts mainly stimulate 
the Th1 response and might lead to a shift from HMI to CMI. 
Stimulation of the CMI response by triphala extract might have 
advantages in terms of resistance to intracellular infections by 
parasites and viruses and may be beneficial in the treatment of 
allergy and autoimmune disease.  
It has been noted that therapeutic activity of herbs is due to their 
chemical complexity. Two bioactive compounds acting at the same 
site might have an additive effect, while two or more bioactive 
compounds acting at different sites might have a synergistic effect 
and possibly improved higher activity by 50 to 200-fold comparing 
to the equivalent concentrations of the isolated compounds [30]. Our 
results show that the change in the Th1/Th2 ratio by triphala was 
greater than that caused by the three single extracts. Thus, it might 
be stated that the complexity of mixed herbs could promote 
effectiveness regarding the immunological response over the use of 
single herbs. After simulating infection by LPS induction, only the F1 
extract decreased the IFN-γ/IL-10 ratio to close to the normal level. 
These findings suggest that the F1 extract could restore the balance 
of immunity by shifting to a Th2 response. Anti-allergy activity of 
triphala extract has been shown to decrease sensitivity to bronchial 
allergen exposure in ovalbumin-sensitised mice [31]. Triphala also 
has anti-inflammatory activity on the inhibition of the complement 
system, HMI response (assessed by the delayed type 
hypersensitivity (DTH) assay in rat) and phytohaemagglutinin-
induced T-lymphocyte proliferation [32]. Therefore, triphala could 
be a good candidate for anti-allergy and anti-inflammatory 
treatment of immune deficiency disorders.  
The immunomodulatory effect of triphala (in equal proportions) was 
also reported in albino rats with noise-induced stress. An increase in 
serum antibody titres and IL-4, a reduction in IL-2 and IFN-
γ expression,  and a decline in the pan-T, CD4+/CD8+lymphocyte 
phenotype in the spleen were observed [33]. Triphala also inhibited 
the CMI response, reduced foot pad swelling and decreased 
leukocyte migration inhibition (LMI) [34], as well as the activation of 
neutrophils [35]. Different experimental models, the conditions of 
cell induction and the tested concentrations might cause variations 
in the results.  
Increases in the production of the cytokines IL-2, IFN-γ, TNF-α and IL-
12 could lead to a Th1-type cellular response, while increased 
expression of IL-4 and IL-6 could lead to a Th2-type humoral response 
[36]. It had been found that several cancer vaccines, especially those 
with immune adjuvants, significantly activate the CMI response, 
resulting in IL-2, IFN-γ, TNF-α and IL-10 expression [37]. Therefore, 
triphala extracts, especially F1, might be a promising extract for 
further investigation as cancer vaccine adjuvants. The cell viability 
assay by using the MTT technique showed that none of the tested 
extracts were toxic to MOLT-4 cells (viability>90%). Moreover, F1, T. 
bellerica and P. emblica extracts led to T-cell proliferation, which 
was possibly related to the increase in IFN-γ production. A previous 
study reported that a triphala aqueous extract had a cytotoxic effect 
on the human breast cancer cell line MCF-7 and barcl-95 
transplantable mouse thymic lymphocytes, but it was not toxic to 
normal cells such as breast epithelial cells, MCF-10F cells, human 
peripheral blood mononuclear cells, and mouse liver and spleen 
cells. The possible mechanism might correlate with the response to 
ROS production in cancer cells [38]. These studies support our 
conclusion that triphala is safe for normal cells and might have an 
anti-cancer effect. Gallic acid and other phenolic compounds might 
be responsible for this activity [39].  
A mixture containing several components could have broad 
specificity and low affinity at the site of action. In some cases, this 
would have be more efficacious and safer than a substance with high 
affinity and specificity [40, 41]. Herbal mixtures may reduce adverse 
effects by buffering the toxicity that may occur when using a single 
extract or specific compounds [42]. Therefore, the complexity of the 
triphala mixture may provide greater pharmacological efficacy, 
lower toxicity and fewer side effects compared to single extracts.  
Herbal or mixed herbal formulations which have anti-inflammatory 
effects and are used for the treatment of immune-related diseases 
might be defined as immunomodulators [43]. Immunomodulators 
also include herbs that affect various immunological molecules such 
as cytokines, adhesion molecules, nitric oxide, hormones, 
neurotransmitters and peptides [44]. Since triphala extracts affect 
IFN-γ and IL-10 production by T lymphocytes (MOLT-4 cells), we can 
state that triphala extract is an immunomodulator.  
We can conclude that triphala extract has immunomodulatory activity, 
supporting the Th1 response more than the Th2 response. The present 
study confirms the traditional uses of triphala related to its 
immunological applications. Preparation of triphala with various 
proportions of T. bellerica, T. chebula and P. emblica affected the 
immunological pattern. F4, an equal proportion of triphala extract which 
is recommended for daily use, could be applied as a healthy herbal drink. 
Interestingly, the triphala extract F1, which contained a high proportion 
of T. bellerica, could be recommended for the treatment of disorders with 
a Th2 imbalance such as allergy and autoimmune disease, or applied 
with a cancer vaccine to stimulate a shift to a Th2 response. However, the 
concentration of each component in the product should be carefully 
determined. Detailed insight into the molecular mode of action of 
triphala extract leading to the observed immunomodulatory activity is 
lacking and further study is required. 
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